ARVINAS, INC. (ARVN) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 316.70M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $316.70M | (m) | (m) |
| 2026-03-31 | (m) | $89.40M | (m) | (m) |
| 2025-12-31 | (m) | $262.60M | (m) | (m) |
| 2025-09-30 | (m) | $312.30M | (m) | (m) |
| 2025-06-30 | (m) | $372.80M | (m) | (m) |
| 2025-03-31 | (m) | $426.90M | (m) | (m) |
| 2024-12-31 | (m) | $263.40M | (m) | (m) |
| 2024-09-30 | (m) | $161.10M | (m) | (m) |
| 2024-06-30 | (m) | $93.30M | (m) | (m) |
| 2024-03-31 | (m) | $71.30M | (m) | (m) |
| 2023-12-31 | (m) | $78.50M | (m) | (m) |
| 2023-09-30 | (m) | $159.40M | (m) | (m) |
| 2023-06-30 | (m) | $158.10M | (m) | (m) |
| 2023-03-31 | (m) | $137.40M | (m) | (m) |
| 2022-12-31 | (m) | $131.40M | (m) | (m) |
| 2022-09-30 | (m) | $112.20M | (m) | (m) |
| 2022-06-30 | (m) | $91.10M | (m) | (m) |
| 2022-03-31 | (m) | $65.40M | (m) | (m) |
| 2021-12-31 | (m) | $46.70M | (m) | (m) |
| 2021-09-30 | (m) | $22.60M | (m) | (m) |
| 2021-06-30 | (m) | $20.90M | (m) | (m) |
| 2021-03-31 | (m) | $21.10M | (m) | (m) |
| 2020-12-31 | (m) | $21.80M | (m) | (m) |
| 2020-09-30 | (m) | $24.40M | (m) | (m) |
| 2020-06-30 | (m) | $22.30M | (m) | (m) |
| 2020-03-31 | (m) | $20.50M | (m) | (m) |
| 2019-12-31 | (m) | $18.30M | (m) | (m) |
| 2019-09-30 | (m) | $16.80M | (m) | (m) |
| 2019-06-30 | (m) | $14.79M | (m) | (m) |
| 2019-03-31 | (m) | $14.19M | (m) | (m) |
| 2018-12-31 | (m) | $14.30M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $11.75M | (m) | (m) |
| 2018-03-31 | (m) | $10.02M | (m) | (m) |
| 2017-12-31 | (m) | $7.58M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |